Clinical Trials Logo

Nonmalignant Diseases clinical trials

View clinical trials related to Nonmalignant Diseases.

Filter by:
  • None
  • Page 1

NCT ID: NCT03609840 Completed - Sickle Cell Disease Clinical Trials

Study of Thiotepa and TEPA Drug Exposure in Pediatric Hematopoietic Stem Cell Transplant Patients

Start date: May 24, 2017
Phase:
Study type: Observational

Thiotepa is a chemotherapy drug used extensively in bone marrow transplantation. Thiotepa is a prodrug that undergoes metabolic conversion in the liver by CYP2B6 and CYP3A4 to its primary active metabolite, triethylene phosphoramide (TEPA). The goal of this study is to determine what causes some children to have different drug concentrations of thiotepa and TEPA in their bodies and if drug levels are related to whether or not a child experiences severe side-effects during their bone marrow transplant. The hypothesis is that certain clinical and genetic factors cause changes in thiotepa and TEPA drug levels in pediatric bone marrow transplant patients and that high levels may cause severe side-effects.

NCT ID: NCT03609827 Completed - Sickle Cell Disease Clinical Trials

Study of Melphalan Drug Exposure in Pediatric Hematopoietic Stem Cell Transplant Patients

Start date: September 1, 2015
Phase:
Study type: Observational

Melphalan is a chemotherapy drug used extensively in bone marrow transplantation. The goal of this study is to determine what causes some children to have different drug concentrations of melphalan in their bodies and if drug levels are related to whether or not a child experiences severe side-effects during their bone marrow transplant. The hypothesis is that certain clinical and individual factors cause changes in melphalan drug levels in pediatric bone marrow transplant patients and that high levels may cause severe side-effects.

NCT ID: NCT03609814 Completed - Sickle Cell Disease Clinical Trials

Study of Clofarabine and Fludarabine Drug Exposure in Pediatric Bone Marrow Transplantation (HCT)

Start date: January 26, 2016
Phase:
Study type: Observational

Fludarabine and clofarabine are chemotherapy drugs used extensively in bone marrow transplantation. The goal of this study is to determine what causes some children to have different drug concentrations of clofarabine and fludarabine in their bodies and if drug levels are related to whether or not a child experiences severe side-effects during their bone marrow transplant. The hypothesis is that clinical and individual factors cause changes in clofarabine and fludarabine drug levels in pediatric bone marrow transplant patients and that high levels may cause severe side-effects.

NCT ID: NCT01316549 Completed - Sickle Cell Disease Clinical Trials

Study of Fludarabine Drug Exposure in Pediatric Bone Marrow Transplantation

HCT
Start date: January 1, 2011
Phase:
Study type: Observational

Fludarabine is a chemotherapy drug used extensively in bone marrow transplantation. The goal of this study is to determine what causes some children to have different drug concentrations of fludarabine in their bodies and if drug levels are related to whether or not a child experiences severe side-effects during their bone marrow transplant. The hypothesis is that clinical and genetic factors cause changes in fludarabine drug levels in pediatric bone marrow transplant patients and that high levels may cause severe side-effects.